Keith Wilson has joined Syrrx as vice president of technology, responsible for implementing technology strategies in support of the San Diego-based company’s protein structure determination and drug discovery objectives, Syrrx said last week.
Wilson most recently served as a project leader at Vertex, where he helped manage an $800 million kinase partnership with Novartis. Syrrx said in a statement that Wilson has solved more than 100 inhibitor enzyme complexes and participated in the design of three compounds currently in Phase II clinical evaluation.
BSI Proteomics has named its co-founder and president Len Arnowitz chair of the board of directors, where he will direct the company’s strategic plan for expanding in the field of protein structure determination and drug design, the Gaithersburg, Md.-based company said last week.
Although Arnowitz would relinquish his role as president, the company did not name an immediate replacement to take over managing day-to-day research and product development. BSI Proteomics has won several SBIR grants from NIH and NASA to develop high-throughput protein crystallization technology in low-gravity and other altered environments.
Hannover, Germany-based BioVision has named Thorlef Spickschen, a former CEO of Knoll/BASF-Pharma, and Berthold Hackl, a managing partner at Heidelberg Innovation, to its supervisory board, the company said last week. In addition to his involvement in the biotech industry, Spickschen has also worked at Eli Lilly and Boehringer Mannheim. BioVision’s proteomics technology involves the discovery of peptides associated with diseases such as cancer, Alzheimer’s, and diabetes. Biovision also said last week that it had received 15 million euros ($12.9 million) in second-round financing.